Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 14/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6860728 | 1.00 | PIM1 (0.37) | PIM1ARCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6860724 | 1.00 | PIM1 (0.37) | PIM1ARCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3568982 | 0.88 | AR (0.38) | PIM1ARCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4597253 | 0.88 | AR (0.38) | PIM1ARCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4597254 | 0.88 | AR (0.38) | PIM1ARCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13269795 | 0.85 | AR (0.36) | ARCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6859327 | 0.85 | AR (0.36) | ARCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3570406 | 0.85 | AR (0.36) | ARCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6859331 | 0.85 | AR (0.36) | ARCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23134696 | 0.84 | AR (0.52) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040010037-A1 | Cyanophenyl derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2004-01-15 | — | — | US | claimed |
| US-7666873-B2 | N-phenyl-(2R,5S)dimethylpiperazine derivative | ASTELLAS PHARMA INC. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20080214543-A1 | N-Phenyl-(2R,5S)Dimethylpiperazine Derivative | ASTELLAS PHARMA INC. (JP) | 2008-09-04 | — | — | US | disclosed |
| US-7297698-B2 | N-phenyl-(2R,5S) dimethylpiperazine derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-20 | — | — | US | disclosed |
| US-20050261303-A1 | N-phenyl-(2r,5s) dimethylpiperadine derivative | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1557411-A1 | N-PHENYL-(2R,5S)DIMETHYLPIPERADINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261303-A1 | N-phenyl-(2r,5s) dimethylpiperadine derivative | BPHL, QDPR, SRD5A2 | PIM1 2623/4885AR 5/4885CHRNB2 4190/4885 |
| US-20040010037-A1 | Cyanophenyl derivative | BPHL, AR, KLK3 | PIM1 1620/4885AR 2/4885CHRNB2 3336/4885 |
| US-20080214543-A1 | N-Phenyl-(2R,5S)Dimethylpiperazine Derivative | BPHL, AR, SRD5A2 | PIM1 2772/4885AR 2/4885CHRNB2 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.